Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

@article{Nardin2006LiposomalMT,
  title={Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.},
  author={Alessandra Nardin and M-L Lefebvre and Karine Labroqu{\`e}re and Olivier Faure and J-P Abastado},
  journal={Current cancer drug targets},
  year={2006},
  volume={6 2},
  pages={123-33}
}
About one third of osteosarcoma patients develop lung metastasis refractory to chemotherapy. Recent studies indicate that biological response modifiers activating the patient's immune system may help controlling minimal residual disease via pathways distinct from those used by cytotoxic drugs, and therefore prove effective against tumor resistance. Muramyl tripeptide phosphatidylethanolamine (MTP-PE) is a synthetic lipophilic glycopeptide capable of activating monocytes and macrophages to a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

Nanomedicine applied to translational oncology: A future perspective on cancer treatment.

Nanomedicine : nanotechnology, biology, and medicine • 2016
View 4 Excerpts
Highly Influenced

Particles and Nanoparticles in Pharmaceutical Products

AAPS Advances in the Pharmaceutical Sciences Series • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…